Belenos Biosciences Reports Positive Phase 2 BEL512 Results.
Sarasota, Fla., August 11, 2026 Belenos Biosciences announced positive topline results from a Phase 2 clinical trial of BEL512...
Biotech
Advertisement
Boulevard Bio Launches with $65M to Advance Immunology
NEW YORK, New York, August 12, 2026 Boulevard Bio has emerged from stealth with approximately $65 million in financing...
Neumora Therapeutics Announces Positive NMRA-215 Toxicology Findings
WATERTOWN, Mass., July 27, 2026 Neumora Therapeutics announced positive preclinical toxicology results for NMRA-215, its investigational brain-penetrant oral NLRP3...
FibroBiologics Advances CYWC628 DFU Trial Manufacturing
HOUSTON, July 7, 2026 FibroBiologics, Inc. has announced the successful completion of the third manufacturing batch of its investigational...
Genentech Wins FDA Priority Review for Enspryng in Thyroid Eye Disease
SOUTH SAN FRANCISCO, Calif., June 29, 2026 Genentech, a member of the Roche Group, announced that the U.S. Food...
Advertisements
Ribo’s RBD1119 Moves Into Phase 2 Development for Coronary Artery Disease
SUZHOU, China, May 29, 2026 Suzhou Ribo Life Science and Ribocure Pharmaceuticals (collectively “Ribo”) have announced the submission of...
Antengene Expands Oncology Pipeline With Phase III ATG-022 Gastric Cancer Trial
SHANGHAI and HONG KONG, China, May 28, 2026 Antengene has announced a major clinical development milestone after receiving endorsement...
Biogen, Denali End BIIB122 Parkinson’s Program
CAMBRIDGE, Massachusetts and SOUTH SAN FRANCISCO, California, May 21, 2026 Biogen Inc. and Denali Therapeutics Inc. announced that the...
MaaT Pharma Receives Negative CHMP Trend for MaaT013 in aGvHD
Lyon, France, May 20, 2026 MaaT Pharma announced that the Committee for Medicinal Products for Human Use (CHMP) of...
BriaCell Expands Women’s Cancer Immunotherapy Pipeline
PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 BriaCell Therapeutics announced the expansion of its oncology pipeline with the...
Advertisement
